Search

Your search keyword '"Fratino, Lucia"' showing total 316 results
Start Over Author "Fratino, Lucia"
316 results on '"Fratino, Lucia"'

1. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study

Author

Messina, Carlo, Catalano, Martina, Roviello, Giandomenico, Gandini, Annalice, Maruzzo, Marco, De Giorgi, Ugo, Pedrazzoli, Paolo, Sbrana, Andrea, Zucal, Paolo Andrea, Masini, Cristina, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Catalano, Fabio, Fratino, Lucia, Pipitone, Stefania, Ricotta, Riccardo, Panni, Stefano, Mollica, Veronica, Soraru, Mariella, Prati, Veronica, Atzori, Francesco, Di Napoli, Marilena, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nole, Franco, Malgeri, Andrea, Tudini, Marianna, Vignani, Francesca, Cavo, Alessia, Signori, Alessio, Banna, Giuseppe Luigi, Rescigno, Pasquale, Buti, Sebastiano, Rebuzzi, Sara Elena, and Fornarini, Giuseppe

Published
2024
Full Text
View/download PDF

2. Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study

Author

Fratino, Lucia, Polesel, Jerry, Giunta, Emilio Francesco, Maruzzo, Marco, Buti, Sebastiano, Hassan, Mona Ali, Basso, Umberto, Rebuzzi, Sara Elena, De Giorgi, Ugo, Cinausero, Marika, Lipari, Helga, Gamba, Teresa, Bimbatti, Davide, Dri, Arianna, Ermacora, Paola, Vignani, Francesca, Fornarini, Giuseppe, Rescigno, Pasquale, and Banna, Giuseppe Luigi

Published
2024
Full Text
View/download PDF

3. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

Author

Altavilla, Amelia, Atzori, Francesco, Banna, Giuseppe Luigi, Barni, Sandro, Basso, Umberto, Bauckneht, Matteo, Berardi, Rossana, Berruti, Alfredo, Bertoldo, Francesco, Bimbatti, Davide, Boccardo, Francesco, Buti, Sebastiano, Buttigliero, Consuelo, Caffo, Orazio, Calabrò, Fabio, Cattrini, Carlo, Cellini, Francesco, Conteduca, Vincenza, Cursano, Maria Concetta, De Feo, Giulia, De Giorgi, Ugo, Di Lorenzo, Giuseppe, Di Maio, Massimo, Di Napoli, Marilena, Ermacora, Paola, Fornarini, Giuseppe, Fratino, Lucia, Fusco, Vittorio, Gernone, Angela, Ibrahim, Toni, Lanzetta, Gaetano, Malgeri, Andrea, Maruzzo, Marco, Masini, Cristina, Messina, Carlo, Mosca, Alessandra, Naglieri, Emanuele, Nolè, Franco, Ortega, Cinzia, Palermo, Andrea, Pantano, Francesco, Prati, Veronica, Procopio, Giuseppe, Rescigno, Pasquale, Roberto, Michela, Rossetti, Sabrina, Roviello, Giandomenico, Santini, Daniele, Stellato, Marco, Tambaro, Rosa, Toma, Ilaria, Tucci, Marcello, Valsecchi, Anna Amela, Verzoni, Elena, Zanardi, Elisa, Zucali, Paolo Andrea, Cursano, M.C., Valsecchi, A.A., Pantano, F., Di Maio, M., Procopio, G., Berruti, A., Bertoldo, F., Tucci, M., De Giorgi, U., and Santini, D.

Published
2024
Full Text
View/download PDF

4. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)

Author

Damassi, Alessandra, Cremante, Malvina, Signori, Alessio, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Giudice, Giulia Claire, Maruzzo, Marco, Procopio, Giuseppe, Sorarù, Mariella, Di Napoli, Marilena, Fratino, Lucia, Santini, Daniele, Grillone, Francesco, Ballestrin, Melissa, Dionese, Michele, Nasso, Cecilia, Catalano, Fabio, Murianni, Veronica, Rescigno, Pasquale, Anpalakhan, Shobana, Banna, Giuseppe Luigi, Basso, Umberto, and Buti, Sebastiano

Published
2024
Full Text
View/download PDF

6. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Author

Anpalakhan, Shobana, Signori, Alessio, Cortellini, Alessio, Verzoni, Elena, Giusti, Raffaele, Aprile, Giuseppe, Ermacora, Paola, Catino, Annamaria, Pipitone, Stefania, Di Napoli, Marilena, Scotti, Vieri, Mazzoni, Francesca, Guglielmini, Pamela F., Veccia, Antonello, Maruzzo, Marco, Schinzari, Giovanni, Casadei, Chiara, Grossi, Francesco, Rizzo, Mimma, Montesarchio, Vincenzo, Verderame, Francesco, Mencoboni, Manlio, Zustovich, Fable, Fratino, Lucia, Accettura, Caterina, Cinieri, Saverio, Tondini, Carlo Alberto, Camerini, Andrea, Banzi, Maria Chiara, Sorarù, Mariella, Zucali, Paolo Andrea, Vignani, Francesca, Ricciardi, Serena, Russo, Antonio, Cosenza, Agnese, Di Maio, Massimo, De Giorgi, Ugo, Pignata, Sandro, Giannarelli, Diana, Pinto, Carmine, Buti, Sebastiano, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Rescigno, Pasquale, Addeo, Alfredo, Banna, Giuseppe L., and Bersanelli, Melissa

Published
2023
Full Text
View/download PDF

7. Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study

Author

Bersanelli, Melissa, Verzoni, Elena, Cortellini, Alessio, Giusti, Raffaele, Calvetti, Lorenzo, Ermacora, Paola, Di Napoli, Marilena, Catino, Annamaria, Guadalupi, Valentina, Guaitoli, Giorgia, Scotti, Vieri, Mazzoni, Francesca, Veccia, Antonello, Guglielmini, Pamela Francesca, Perrone, Fabiana, Maruzzo, Marco, Rossi, Ernesto, Casadei, Chiara, Montesarchio, Vincenzo, Grossi, Francesco, Rizzo, Mimma, Travagliato Liboria, Maria Grazia, Mencoboni, Manlio, Zustovich, Fable, Fratino, Lucia, Accettura, Caterina, Cinieri, Saverio, Camerini, Andrea, Sorarù, Mariella, Zucali, Paolo Andrea, Ricciardi, Serena, Russo, Antonio, Negrini, Giorgia, Banzi, Maria Chiara, Lacidogna, Gaetano, Fornarini, Giuseppe, Laera, Letizia, Mucciarini, Claudia, Santoni, Matteo, Mosillo, Claudia, Bonetti, Andrea, Longo, Lucia, Sartori, Donata, Baldini, Editta, Guida, Michele, Iannopollo, Mauro, Bordonaro, Roberto, Morelli, Maria Francesca, Tagliaferri, Pierosandro, Spada, Massimiliano, Ceribelli, Anna, Silva, Rosa Rita, Nolè, Franco, Beretta, Giordano, Giovanis, Petros, Santini, Daniele, Luzi Fedeli, Stefano, Nanni, Oriana, Maiello, Evaristo, Labianca, Roberto, Pinto, Carmine, Clemente, Alberto, Tognetto, Michele, De Giorgi, Ugo, Pignata, Sandro, Di Maio, Massimo, Buti, Sebastiano, and Giannarelli, Diana

Published
2023
Full Text
View/download PDF

8. The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network

Author

Giunta, Emilio Francesco, De Padova, Silvia, Anpalakhan, Shobana, De Giorgi, Ugo, Maruzzo, Marco, Rebuzzi, Sara Elena, Cinausero, Marika, Fratino, Lucia, Lipari, Helga, Gamba, Teresa, Bimbatti, Davide, Dri, Arianna, Ermacora, Paola, Vignani, Francesca, Basso, Umberto, Buti, Sebastiano, Gandini, Annalice, Cremante, Malvina, Fornarini, Giuseppe, Rescigno, Pasquale, and Banna, Giuseppe Luigi

Published
2023
Full Text
View/download PDF

10. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Author

Rebuzzi, Sara Elena, Signori, Alessio, Banna, Giuseppe Luigi, Gandini, Annalice, Fornarini, Giuseppe, Damassi, Alessandra, Maruzzo, Marco, De Giorgi, Ugo, Basso, Umberto, Chiellino, Silvia, Galli, Luca, Zucali, Paolo Andrea, Fantinel, Emanuela, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Boccardo, Francesco, Fratino, Lucia, Pipitone, Stefania, Ricotta, Riccardo, Panni, Stefano, Mollica, Veronica, Sorarù, Mariella, Santoni, Matteo, Cortellini, Alessio, Prati, Veronica, Soto Parra, Hector Josè, Santini, Daniele, Atzori, Francesco, Di Napoli, Marilena, Caffo, Orazio, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nolè, Franco, Vignani, Francesca, Cavo, Alessia, Roviello, Giandomenico, Rescigno, Pasquale, and Buti, Sebastiano

Published
2022
Full Text
View/download PDF

12. Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.

Author

Catalano, Martina, Rebuzzi, Sara Elena, Maruzzo, Marco, De Giorgi, Ugo, Buti, Sebastiano, Galli, Luca, Fornarini, Giuseppe, Zucali, Paolo Andrea, Claps, Melanie, Chiellino, Silvia, Zampiva, Ilaria, Pipitone, Stefania, Ricotta, Riccardo, Sorarù, Mariella, Mollica, Veronica, Tudini, Marianna, Fratino, Lucia, Prati, Veronica, Caffo, Orazio, and Atzori, Francesco

Subjects
TREATMENT effectiveness, BONE metastasis, SODIUM, IMMUNE checkpoint inhibitors, RENAL cell carcinoma, HYPERNATREMIA
Abstract

Background: Immune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role of natremia in pretreated RCC patients with BMs receiving immunotherapy. Materials and Methods: This retrospective multicenter study included RCC patients with BMs receiving nivolumab as second-line therapy or beyond. Inclusion criteria involved baseline sodium levels (pre-ICI) and sodium levels after 4 weeks of nivolumab initiation (post-ICI). The population was divided into two groups based on the median value, and response rates, progression-free survival (PFS), and overall survival (OS) were assessed. Results: Among 120 eligible patients, those with pre-treatment sodium levels =140 mEq/L showed longer OS (18.7 vs. 12.0 months, p=0.04). Pre-treatment sodium levels =140 mEq/L were associated with better OS compared to levels <140 mE/L (18.7 vs. 12.0, p=0.04). Post-treatment sodium levels =140mEq/L were associated with improved PFS (9.6 vs. 3.2 months) and OS (25.1 vs. 8.8 months) (p=0.05 and p<0.01, respectively). Patients with consistent sodium levels =140 mEq/L at both time points exhibited the best outcomes compared to those with lower values (PFS 11.5 vs. 3.3 months and OS 42.2 vs. 9.0 months, respectively, p<0.01). Disease control rate was significantly higher in the latter group (p<0.01). Multivariate analysis confirmed the prognostic significance of sodium levels. Conclusion: Elevated sodium levels (=140 mEq/L) pre- and post-ICI treatment correlate with better survival outcomes in mRCC patients with BMs. This finding suggests sodium level assessment as a potential prognostic factor in these patients and warrants further investigation, particularly in combination immunotherapy settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study

Author

Messina, Carlo, primary, Catalano, Martina, additional, roviello, giandomenico, additional, Gandini, Annalice, additional, Maruzzo, Marzo, additional, De Giorgi, Ugo, additional, Pedrazzoli, Paolo, additional, Sbrana, Andrea, additional, Zucali, Paolo Ansrea, additional, Masini, Cristina, additional, Naglieri, Emanuele, additional, Procopio, Giuseppe, additional, Milella, Michele, additional, Catalano, Fabio, additional, Fratino, Lucia, additional, Pipitone, Stefania, additional, Ricotta, Riccardo, additional, Panni, Stefano, additional, Mollica, Veronica, additional, Atzori, Francesco, additional, Napoli, Marilena Di, additional, Messina, Marco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Malgeri, Andrea, additional, Tudini, Marianna, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Signori, Alessio, additional, Banna, Giuseppe Luigi, additional, Rescigno, Pasquale, additional, Buti, Stefano, additional, Rebuzzi, Sara Elena, additional, and Fornarini, Giuseppe, additional

Published
2024
Full Text
View/download PDF

14. A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

Author

Sepe, Pierangela, primary, Procopio, Giuseppe, additional, Pircher, Chiara Carlotta, additional, Basso, Umberto, additional, Caffo, Orazio, additional, Cappelletti, Vera, additional, Claps, Melanie, additional, De Giorgi, Ugo, additional, Fratino, Lucia, additional, Guadalupi, Valentina, additional, Miodini, Patrizia, additional, De Marco, Cinzia, additional, Perrucci, Bruno, additional, Mennitto, Alessia, additional, Santini, Daniele, additional, Spina, Francesco, additional, Stellato, Marco, additional, de Braud, Filippo, additional, and Verzoni, Elena, additional

Published
2024
Full Text
View/download PDF

16. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region

Author

Maruzzo, Marco, Basso, Umberto, Borsatti, Eugenio, Evangelista, Laura, Alongi, Filippo, Caffo, Orazio, Maines, Francesca, Galuppo, Sara, De Vivo, Rocco, Zustovich, Fable, Palleschi, Dario, Zivi, Andrea, Sava, Teodoro, Sorarù, Mariella, Iacovelli, Roberto, Nicodemo, Maurizio, Baier, Susanne, Fratino, Lucia, and Zagonel, Vittorina

Published
2019
Full Text
View/download PDF

17. Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab

Author

Catalano, Martina, primary, Rebuzzi, Sara Elena, additional, Maruzzo, Marco, additional, De Giorgi, Ugo, additional, Buti, Sebastiano, additional, Galli, Luca, additional, Fornarini, Giuseppe, additional, Zucali, Paolo Andrea, additional, Procopio, Giuseppe, additional, Chiellino, Silvia, additional, Milella, Michele, additional, Catalano, Fabio, additional, Pipitone, Stefania, additional, Ricotta, Riccardo, additional, Sorarù, Mariella, additional, Mollica, Veronica, additional, Tudini, Marianna, additional, Fratino, Lucia, additional, Prati, Veronica, additional, Caffo, Orazio, additional, Atzori, Francesco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Di Napoli, Marilena, additional, Malgeri, Andrea, additional, Naglieri, Emanuele, additional, Signori, Alessio, additional, Banna, Giuseppe Luigi, additional, Rescigno, Pasquale, additional, Antonuzzo, Lorenzo, additional, and Roviello, Giandomenico, additional

Published
2023
Full Text
View/download PDF

18. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)

Author

Damassi, Alessandra, primary, Cremante, Malvina, additional, Signori, Alessio, additional, Rebuzzi, Sara Elena, additional, Fornarini, Giuseppe, additional, Giudice, Giulia Claire, additional, Maruzzo, Marco, additional, Procopio, Giuseppe, additional, Sorarù, Mariella, additional, Di Napoli, Marilena, additional, Fratino, Lucia, additional, Santini, Daniele, additional, Grillone, Francesco, additional, Ballestrin, Melissa, additional, Dionese, Michele, additional, Nasso, Cecilia, additional, Catalano, Fabio, additional, Murianni, Veronica, additional, Rescigno, Pasquale, additional, Anpalakhan, Shobana, additional, Banna, Giuseppe Luigi, additional, Basso, Umberto, additional, and Buti, Sebastiano, additional

Published
2023
Full Text
View/download PDF

21. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.

Author

Murianni, Veronica, Signori, Alessio, Buti, Sebastiano, Rebuzzi, Sara Elena, Bimbatti, Davide, De Giorgi, Ugo, Chiellino, Silvia, Galli, Luca, Zucali, Paolo Andrea, Masini, Cristina, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Fratino, Lucia, and Baldessari, Cinzia

Subjects
RENAL cell carcinoma, IMMUNE checkpoint inhibitors, NIVOLUMAB, TREATMENT failure
Abstract

Background: Immunotherapies exhibit peculiar cancer response patterns in contrast to chemotherapy and targeted therapy. Some patients experience disease response after initial progression or durable responses after treatment interruption. In clinical practice, immune checkpoint inhibitors may be continued after radiological progression if clinical benefit is observed. As a result, estimating progression-free survival (PFS) based on the first disease progression may not accurately reflect the actual benefit of immunotherapy. Methods: The Meet-URO 15 study was a multicenter retrospective analysis of 571 pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab. Time to strategy failure (TSF) was defined as the interval from the start of immunotherapy to definitive disease progression or death. This posthoc analysis compared TSF to PFS and assess the response and survival outcomes between patients treatated beyond progression (TBP) and non- TBP. Moreover, we evaluated the prognostic accuracy of the Meet-URO score versus the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score based on TSF and PFS. Results: Overall, 571 mRCC patients were included in the analysis. Median TSF was 8.6 months (95% CI: 7.0 - 10.1), while mPFS was 7.0 months (95% CI: 5.7 - 8.5). TBP patients (N = 93) had significantly longer TSF (16.3 vs 5.5 months; p < 0.001) and overall survival (OS) (34.8 vs 17.9 months; p < 0.001) but similar PFS compared to non-TBP patients. In TBP patients, a median delay of 9.6 months (range: 6.7-16.3) from the first to the definitive disease progression was observed, whereas non-TBP patients had overlapped median TSF and PFS (5.5 months). Moreover, TBP patients had a trend toward a higher overall response rate (33.3% vs 24.3%; p = 0.075) and disease control rate (61.3% vs 55.5%; p = 0.31). Finally, in the whole population the Meet-URO score outperformed the IMDC score in predicting both TSF (c-index: 0.63 vs 0.59) and PFS (0.62 vs 0.59). Conclusion: We found a 2-month difference between mTSF and mPFS in mRCC patients receiving nivolumab. However, TBP patients had better outcomes, including significantly longer TSF and OS than non-TBP patients. The Meet-URO score is a reliable predictor of TSF and PFS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (Meet-URO 31).

Author

Stellato, Marco, Procopio, Giuseppe, Romei, Chiara, Colantonio, Sara, Cattaneo, Laura, Claps, Melanie, Guadalupi, Valentina, Sepe, Pierangela, Basso, Umberto, Buti, Sebastiano, Fornarini, Giuseppe, Vignani, Francesca, Fratino, Lucia, Iacovelli, Roberto, Nole, Franco, Di Napoli, Marilena, Zucali, Paolo Andrea, De Braud, Filippo G., and Del Re, Marzia

Published
2024
Full Text
View/download PDF

23. Outcomes of elderly patients (pts) treated with docetaxel (DOC) for metastatic castration-sensitive prostate cancer (mCSPC): Results from ECHOS, a multicenter Italian observational study.

Author

Caffo, Orazio, Maruzzo, Marco, Pravisano, Federico, ButtIgliero, Consuelo, Sorarù, Mariella, Masini, Cristina, Gori, Stefania, Sabbatini, Roberto, Pappalardo, Annalisa, Cattrini, Carlo, Fornarini, Giuseppe, Vittimberga, Isabella, Rametta, Alessandro, Zucali, Paolo Andrea, Fantinel, Emanuela, Grillone, Francesco, Fratino, Lucia, Galli, Luca, Giordano, Monica, and Basso, Umberto

Published
2024
Full Text
View/download PDF

24. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme

Author

Maines, Francesca, Caffo, Orazio, De Giorgi, Ugo, Fratino, Lucia, Lo Re, Giovanni, Zagonel, Vittorina, D'Angelo, Alessandro, Donini, Maddalena, Verderame, Francesco, Ratta, Raffaele, Procopio, Giuseppe, Campadelli, Enrico, Massari, Francesco, Gasparro, Donatello, Ermacora, Paola, Messina, Caterina, Giordano, Monica, Alesini, Daniele, Basso, Umberto, Fraccon, Anna Paola, Vicario, Giovanni, Conteduca, Vincenza, and Galligioni, Enzo

Published
2016
Full Text
View/download PDF

25. Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

Author

Conteduca, Vincenza, Di Tullio, Piergiorgio, Allamprese, Rossana, Bruno, Giuseppina, Lolli, Cristian, Schepisi, Giuseppe, Rosano, Aldo, Giordano, Guido, Garofoli, Marianna, Chiuri, Vincenzo Emanuele, Fratino, Lucia, Zanardi, Elisa, Galli, Luca, Massari, Francesco, Falagario, Ugo, Rescigno, Pasquale, Fornarini, Giuseppe, Sanguedolce, Francesca, Santini, Daniele, Procopio, Giuseppe, Caffo, Orazio, Carrieri, Giuseppe, Landriscina, Matteo, and De Giorgi, Ugo

Abstract

Background: Currently, several therapies are available for metastatic castration-resistant prostate cancer (mCRPC) but no specific clinical factors to personalize treatment. We first sought the prognostic value of duration on androgen-deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) in patients receiving androgen-receptor-signaling inhibitors (ARSI) for mCRPC. Methods: A multicenter cohort of mCRPC patients who started ARSI between July 2011 and October 2021 was identified. Based on their initial disease burden and duration on ADT for HSPC, primary progressive (PP) men were classified into four groups: low/intermediate-risk localized disease (LOC) and high-risk localized/locally advanced disease (LAD) and short-term (ST) &lt; 24 vs. long-term (LT) ADT ≥ 24 months, whereas de novo (DN) mHSPC were subdivided into short-time vs. long-time to CRPC. Results: We included 919 mCRPC patients with a median age of 77 years [interquartile range (IQR) = 71–82)]. Median ADT duration in HSPC was 24 months (IQR = 14–40). Median follow-up was 91 months (IQR = 62–138), median OS and PFS from ARSI start were 20 (IQR 10–32) and 10 months (IQR = 5–19), respectively. In PP developing metastatic disease (n= 655, 71.3%), LOC and LAD with ST ADT had a greater than almost double-risk of death compared to LT ADT (LOC/ST: hazard ratio [HR] = 2.01; 95% CI 1.54–2.64; LAD/ST: HR = 1.73; 95% CI 1.34–2.24; p&lt; 0.001). In the multivariate analysis including age, prognostic cohort, Gleason, ECOG, radical radiotherapy and prostatectomy, groups with ST ADT were associated with worse OS compared to LT ADT (LOC/ST: HR = 1.84; 95% CI 1.38–2.45; p&lt; 0.001; LAD/ST: HR = 1.59; 95% CI 1.21–2.10; p&lt; 0.001), along with ECOG > 2 (HR = 1.55; 95% CI 1.06–2.26; p= 0.03). There were also similar results of PFS. Moreover, long-time to CRPC in patients with history of DN mHSPC (n= 264, 28.7%) resulted in a better OS/PFS (HR = 0.76, 95% CI 0.56–1.02, p= 0.064 and HR = 0.74, 95% CI 0.55–0.99, p= 0.042, respectively). Conclusions: Our study showed that duration on ADT for mHSPC was significantly associated with survival in mCRPC undergoing ARSI. These findings suggest a possible connection between initial management of prostate tumour and a better prognostication in mCRPC. Prospective trials are warranted.

Published
2024
Full Text
View/download PDF

26. Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9.

Author

Mattana, Alvise, primary, Del Re, Marzia, additional, Bimbatti, Davide, additional, Buti, Sebastiano, additional, Claps, Melanie, additional, Di Napoli, Marilena, additional, Fratino, Lucia, additional, Santini, Daniele, additional, Sorarù, Mariella, additional, Grillone, Francesco, additional, Mazzaschi, Giulia, additional, Maruzzo, Marco, additional, Pierantoni, Francesco, additional, Ballestrin, Melissa, additional, De Toni, Chiara, additional, Lai, Eleonora, additional, Dionese, Michele, additional, Zagonel, Vittorina, additional, and Basso, Umberto, additional

Published
2023
Full Text
View/download PDF

27. Prognostic stratification by the Meet-URO score in a real-world elderly population of patients (pts) with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: A subanalysis of the prospective ZEBRA study (Meet-URO 9).

Author

Damassi, Alessandra, primary, Cremante, Malvina, additional, Fornarini, Giuseppe, additional, Signori, Alessio, additional, Buti, Sebastiano, additional, Basso, Umberto, additional, Procopio, Giuseppe, additional, Maruzzo, Marco, additional, Sorarù, Mariella, additional, Di Napoli, Marilena, additional, Fratino, Lucia, additional, Santini, Daniele, additional, Grillone, Francesco, additional, Ballestrin, Melissa, additional, Dionese, Michele, additional, Murianni, Veronica, additional, Catalano, Fabio, additional, Banna, Giuseppe Luigi L., additional, Rescigno, Pasquale, additional, and Rebuzzi, Sara Elena, additional

Published
2023
Full Text
View/download PDF

28. Outcomes of post-progression therapies in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an Italian multicenter observational study (ECHOS trial).

Author

Caffo, Orazio, primary, Maruzzo, Marco, additional, Samuelly, Alessandro, additional, Facchini, Gaetano, additional, Zanardi, Elisa, additional, Nicodemo, Maurizio, additional, Ermacora, Paola, additional, Sorarù, Mariella, additional, Galli, Luca, additional, Cattrini, Carlo, additional, Borsellino, Nicolo, additional, Buti, Sebastiano, additional, Rebuzzi, Sara Elena, additional, Iacovelli, Roberto, additional, Rametta, Alessandro, additional, Calvani, Nicola, additional, Giordano, Monica, additional, Farnesi, Azzurra, additional, Fratino, Lucia, additional, and Basso, Umberto, additional

Published
2023
Full Text
View/download PDF

29. Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9).

Author

Basso, Umberto, primary, Buti, Sebastiano, additional, Verzoni, Elena, additional, Sorarù, Mariella, additional, Di Napoli, Marilena, additional, Fratino, Lucia, additional, Santini, Daniele, additional, Grillone, Francesco, additional, Chiuri, Vincenzo Emanuele Emanuele, additional, Carella, Claudia, additional, Atzori, Francesco, additional, Roviello, Giandomenico, additional, Sartori, Donata, additional, Maruzzo, Marco, additional, Pierantoni, Francesco, additional, Bersanelli, Melissa, additional, Ballestrin, Melissa, additional, De Toni, Chiara, additional, Mattana, Alvise, additional, and Zagonel, Vittorina, additional

Published
2023
Full Text
View/download PDF

30. Impact of vaccination against SARS-CoV-2 on the risk of hospital admission and death among infected patients with urologic cancers: A population-based study in northern Italy.

Author

Fratino, Lucia, primary, Gobbato, Michele, additional, Clagnan, Elena, additional, Taborelli, Martina, additional, Del Zotto, Stefania, additional, Toffolutti, Federica, additional, Burba, Ivana, additional, Tosolini, Francesca, additional, Polimeni, Joseph, additional, and Serraino, Diego, additional

Published
2023
Full Text
View/download PDF

31. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

Author

Stellato, Marco, primary, Buti, Sebastiano, additional, Maruzzo, Marco, additional, Bersanelli, Melissa, additional, Pierantoni, Francesco, additional, De Giorgi, Ugo, additional, Di Napoli, Marilena, additional, Iacovelli, Roberto, additional, Vitale, Maria Giuseppa, additional, Ermacora, Paola, additional, Malgeri, Andrea, additional, Maiorano, Brigida Anna, additional, Prati, Veronica, additional, Mennitto, Alessia, additional, Cavo, Alessia, additional, Santoni, Matteo, additional, Carella, Claudia, additional, Fratino, Lucia, additional, Procopio, Giuseppe, additional, Verzoni, Elena, additional, and Santini, Daniele, additional

Published
2023
Full Text
View/download PDF

32. The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network

Author

Banna, Giuseppe Luigi, primary, Basso, Umberto, additional, Giunta, Emilio Francesco, additional, Fratino, Lucia, additional, Rebuzzi, Sara Elena, additional, Buti, Sebastiano, additional, Maruzzo, Marco, additional, De Giorgi, Ugo, additional, Murianni, Veronica, additional, Cinausero, Marika, additional, Lipari, Helga, additional, Gamba, Teresa, additional, Caffo, Orazio, additional, Bimbatti, Davide, additional, Dri, Arianna, additional, Mosca, Alessandra, additional, Ermacora, Paola, additional, Vignani, Francesca, additional, Msaki, Aichi, additional, Bonifacio, Barbara, additional, Lombardo, Valentina, additional, Conteduca, Vincenza, additional, Fornarini, Giuseppe, additional, and Rescigno, Pasquale, additional

Published
2022
Full Text
View/download PDF

33. The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis

Author

Rebuzzi, Sara Elena, primary, Signori, Alessio, additional, Stellato, Marco, additional, Santini, Daniele, additional, Maruzzo, Marco, additional, De Giorgi, Ugo, additional, Pedrazzoli, Paolo, additional, Galli, Luca, additional, Zucali, Paolo Andrea, additional, Fantinel, Emanuela, additional, Carella, Claudia, additional, Procopio, Giuseppe, additional, Milella, Michele, additional, Boccardo, Francesco, additional, Fratino, Lucia, additional, Sabbatini, Roberto, additional, Ricotta, Riccardo, additional, Panni, Stefano, additional, Massari, Francesco, additional, Sorarù, Mariella, additional, Santoni, Matteo, additional, Cortellini, Alessio, additional, Prati, Veronica, additional, Soto Parra, Hector Josè, additional, Atzori, Francesco, additional, Di Napoli, Marilena, additional, Caffo, Orazio, additional, Messina, Marco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Roviello, Giandomenico, additional, Llaja Obispo, Miguel Angel, additional, Porta, Camillo, additional, Buti, Sebastiano, additional, Fornarini, Giuseppe, additional, and Banna, Giuseppe Luigi, additional

Published
2022
Full Text
View/download PDF

36. Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network

Author

Rescigno, Pasquale, primary, Maruzzo, Marco, additional, Rebuzzi, Sara Elena, additional, Murianni, Veronica, additional, Cinausero, Marika, additional, Lipari, Helga, additional, Fratino, Lucia, additional, Gamba, Teresa, additional, De Giorgi, Ugo, additional, Caffo, Orazio, additional, Bimbatti, Davide, additional, Dri, Arianna, additional, Mosca, Alessandra, additional, Giunta, Emilio Francesco, additional, Ermacora, Paola, additional, Vignani, Francesca, additional, Msaki, Aichi, additional, Bonifacio, Barbara, additional, Lombardo, Valentina, additional, Conteduca, Vincenza, additional, Basso, Umberto, additional, Fornarini, Giuseppe, additional, and Banna, Giuseppe Luigi, additional

Published
2022
Full Text
View/download PDF

38. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

Author

Basso, Umberto, primary, Paolieri, Federico, additional, Rizzo, Mimma, additional, De Giorgi, Ugo, additional, Bracarda, Sergio, additional, Antonuzzo, Lorenzo, additional, Atzori, Francesco, additional, Cartenì, Giacomo, additional, Procopio, Giuseppe, additional, Fratino, Lucia, additional, D’Arcangelo, Manolo, additional, Fornarini, Giuseppe, additional, Zucali, Paolo, additional, Cusmai, Antonio, additional, Santoni, Matteo, additional, Pipitone, Stefania, additional, Carella, Claudia, additional, Panni, Stefano, additional, Deppieri, Filippo, additional, Zagonel, Vittorina, additional, and Tortora, Giampaolo, additional

Published
2022
Full Text
View/download PDF

39. First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry

Author

Galli, Luca, primary, Chiuri, Vincenzo Emanuele, additional, Di Lorenzo, Giuseppe, additional, Pisconti, Salvatore, additional, Rossetti, Sabrina, additional, Sirotova, Zuzana, additional, Muto, Andrea, additional, Petrioli, Roberto, additional, De Tursi, Michele, additional, Sbrana, Andrea, additional, Francolini, Giulio, additional, Ardizzoia, Antonio, additional, Scavelli, Claudio, additional, Satta, Francesco, additional, Quadrini, Silvia, additional, Airoldi, Mario, additional, D’Aniello, Carmine, additional, Bonetti, Andrea, additional, Conforti, Serafino, additional, Aieta, Michele, additional, Beccaglia, Patrizia, additional, Maestri, Antonio, additional, and Fratino, Lucia, additional

Published
2022
Full Text
View/download PDF

40. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)

Author

Basso, Umberto, primary, Procopio, Giuseppe, additional, Fornarini, Giuseppe, additional, Massari, Francesco, additional, Bearz, Alessandra, additional, Fratino, Lucia, additional, Milella, Michele, additional, Bassanelli, Maria, additional, Ermacora, Paola, additional, Bimbatti, Davide, additional, Verzoni, Elena, additional, Rizzo, Mimma, additional, and Porta, Camillo, additional

Published
2021
Full Text
View/download PDF

42. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

Author

Caffo, Orazio, primary, Ortega, Cinzia, additional, Nolè, Franco, additional, Gasparro, Donatello, additional, Mucciarini, Claudia, additional, Aieta, Michele, additional, Zagonel, Vittorina, additional, Iacovelli, Roberto, additional, De Giorgi, Ugo, additional, Facchini, Gaetano, additional, Veccia, Antonello, additional, Palesandro, Erica, additional, Verri, Elena, additional, Buti, Sebastiano, additional, Razzini, Giorgia, additional, Bozza, Giovanni, additional, Maruzzo, Marco, additional, Ciccarese, Chiara, additional, Schepisi, Giuseppe, additional, Rossetti, Sabrina, additional, Maines, Francesca, additional, Kinspergher, Stefania, additional, Fratino, Lucia, additional, Ermacora, Paola, additional, Nicodemo, Maurizio, additional, Giordano, Monica, additional, Sartori, Donata, additional, Scapoli, Daniela, additional, Sabbatini, Roberto, additional, Lo Re, Giovanni, additional, Morelli, Franco, additional, D’Angelo, Alessandro, additional, Vittimberga, Isabella, additional, Lippe, Paolo, additional, Carrozza, Francesco, additional, Messina, Caterina, additional, Galli, Luca, additional, Valcamonico, Francesca, additional, Porta, Camillo, additional, Pappagallo, Giovanni, additional, and Aglietta, Massimo, additional

Published
2021
Full Text
View/download PDF

43. First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry

Author

Galli, Luca, Chiuri, Vincenzo Emanuele, Di Lorenzo, Giuseppe, Pisconti, Salvatore, Rossetti, Sabrina, Sirotova, Zuzana, Muto, Andrea, Petrioli, Roberto, De Tursi, Michele, Sbrana, Andrea, Francolini, Giulio, Ardizzoia, Antonio, Scavelli, Claudio, Satta, Francesco, Quadrini, Silvia, Airoldi, Mario, D’Aniello, Carmine, Bonetti, Andrea, Conforti, Serafino, Aieta, Michele, Beccaglia, Patrizia, Maestri, Antonio, and Fratino, Lucia

Abstract

Background: With the availability of multiple treatment options for metastatic castration-resistant prostate cancer (mCRPC), new real-world data on disease management and drugs’ performance are needed.Methods: We described characteristics, management and clinical outcomes of patients receiving first-line mCRPC treatment within the Italian cohort of the real-world, prospective, international Prostate Cancer Registry. Patients were enrolled consecutively (2013-2016) in 32 Italian sites and followed for 3 years.Results: 238 patients were included: 157 received first-line abiraterone acetate plus prednisone (“abiraterone” thereafter) and 70 first-line docetaxel; 11 patients receiving other treatments were not considered. Compared with docetaxel-treated patients, those receiving abiraterone were significantly older (age ⩾75: 63.7% vs 38.6%), less frequently had a Gleason score >8 (48.2% vs 67.6%, p<0.005) at initial diagnosis, and more frequently an ECOG score ⩾1 (52.7% vs 36.2%, p<0.05) and comorbidities (76.4% vs 57.1%, p<0.05) at baseline; they reported a lower analgesic use (15.3% vs 30%, p<0.005). In the abiraterone group (median follow-up 22.1 months), median time to progression (TTP) and progression-free survival (PFS) were, respectively, 14.4 months (95% confidence interval, CI, 10.6-18.0) and 13.0 months (95% CI, 9.1-16.8); median overall survival (OS) was not reached, and 3-year OS was 59.1%. In the docetaxel treatment group (median follow-up 25.3 months), median TTP, PFS and OS were, respectively, 8.2 months (95% CI, 6.1-10.3), 8.2 months (95% CI, 5.8-10.3) and 33.2 months (95% CI, 19.2-not estimable).Conclusion: This investigation provided valuable information on the overall mCRPC treatment pattern and the effectiveness of first-line abiraterone and docetaxel in a population representative of everyday practice.

Published
2023
Full Text
View/download PDF

45. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

Author

Caffo, Orazio, De Giorgi, Ugo, Fratino, Lucia, Lo Re, Giovanni, Basso, Umberto, DʼAngelo, Alessandro, Donini, Maddalena, Verderame, Francesco, Ratta, Raffaele, Procopio, Giuseppe, Campadelli, Enrico, Massari, Francesco, Gasparro, Donatello, Macrini, Sveva, Messina, Caterina, Giordano, Monica, Alesini, Daniele, Zustovich, Fable, Fraccon, Anna P., Vicario, Giovanni, Conteduca, Vincenza, Maines, Francesca, and Galligioni, Enzo

Published
2015
Full Text
View/download PDF

46. sj-docx-1-tam-10.1177_17588359211019642 – Supplemental material for Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

Author

Rebuzzi, Sara Elena, Signori, Alessio, Banna, Giuseppe Luigi, Maruzzo, Marco, De Giorgi, Ugo, Pedrazzoli, Paolo, Sbrana, Andrea, Zucali, Paolo Andrea, Masini, Cristina, Naglieri, Emanuele, Procopio, Giuseppe, Merler, Sara, Tomasello, Laura, Fratino, Lucia, Baldessari, Cinzia, Ricotta, Riccardo, Panni, Stefano, Mollica, Veronica, Sorarù, Maria, Santoni, Matteo, Cortellini, Alessio, Prati, Veronica, Parra, Hector Josè Soto, Stellato, Marco, Atzori, Francesco, Pignata, Sandro, Messina, Carlo, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nolè, Franco, Vignani, Francesca, Cavo, Alessia, Roviello, Giandomenico, Pierantoni, Francesco, Casadei, Chiara, Bersanelli, Melissa, Chiellino, Silvia, Paolieri, Federico, Perrino, Matteo, Brunelli, Matteo, Iacovelli, Roberto, Porta, Camillo, Buti, Sebastiano, and Fornarini, Giuseppe

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359211019642 for Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) by Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Marco Maruzzo, Ugo De Giorgi, Paolo Pedrazzoli, Andrea Sbrana, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Sara Merler, Laura Tomasello, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Maria Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Marco Stellato, Francesco Atzori, Sandro Pignata, Carlo Messina, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Francesco Pierantoni, Chiara Casadei, Melissa Bersanelli, Silvia Chiellino, Federico Paolieri, Matteo Perrino, Matteo Brunelli, Roberto Iacovelli, Camillo Porta, Sebastiano Buti and Giuseppe Fornarini in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

48. A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.

Author

Sepe, Pierangela, primary, Procopio, Giuseppe, additional, Basso, Umberto, additional, Caffo, Orazio, additional, Cappelletti, Vera, additional, Claps, Melanie, additional, De Giorgi, Ugo, additional, Fratino, Lucia, additional, Guadalupi, Valentina, additional, Miodini, Patrizia, additional, Perrucci, Bruno, additional, Mennitto, Alessia, additional, Santini, Daniele, additional, Spina, Francesco, additional, Ottini, Arianna, additional, De Braud, Filippo G., additional, and Verzoni, Elena, additional

Published
2021
Full Text
View/download PDF

49. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)

Author

Bersanelli, Melissa, primary, Giannarelli, Diana, additional, De Giorgi, Ugo, additional, Pignata, Sandro, additional, Di Maio, Massimo, additional, Clemente, Alberto, additional, Verzoni, Elena, additional, Giusti, Raffaele, additional, Di Napoli, Marilena, additional, Aprile, Giuseppe, additional, Ermacora, Paola, additional, Catino, Annamaria, additional, Scotti, Vieri, additional, Mazzoni, Francesca, additional, Guglielmini, Pamela Francesca, additional, Veccia, Antonello, additional, Maruzzo, Marco, additional, Rossi, Ernesto, additional, Grossi, Francesco, additional, Casadei, Chiara, additional, Ficorella, Corrado, additional, Montesarchio, Vincenzo, additional, Verderame, Francesco, additional, Rizzo, Mimma, additional, Guaitoli, Giorgia, additional, Fratino, Lucia, additional, Accettura, Caterina, additional, Mencoboni, Manlio, additional, Zustovich, Fable, additional, Baldessari, Cinzia, additional, Cinieri, Saverio, additional, Camerini, Andrea, additional, Laera, Letizia, additional, Sorarù, Mariella, additional, Zucali, Paolo Andrea, additional, Guadalupi, Valentina, additional, Leonardi, Francesco, additional, Tiseo, Marcello, additional, Tognetto, Michele, additional, Di Costanzo, Francesco, additional, Pinto, Carmine, additional, Negrini, Giorgia, additional, Russo, Antonio, additional, Migliorino, Maria R, additional, Filetti, Marco, additional, and Buti, Sebastiano, additional

Published
2021
Full Text
View/download PDF

50. Supplementary_Material_-_online_only – Supplemental material for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

Author

Bersanelli, Melissa, Giannarelli, Diana, Giorgi, Ugo De, Pignata, Sandro, Maio, Massimo Di, Verzoni, Elena, Clemente, Alberto, Guadalupi, Valentina, Signorelli, Diego, Tiseo, Marcello, Giusti, Raffaele, Filetti, Marco, Napoli, Marilena Di, Calvetti, Lorenzo, Cappetta, Alessandro, Ermacora, Paola, Zara, Diego, Barbieri, Fausto, Baldessari, Cinzia, Scotti, Vieri, Mazzoni, Francesca, Veccia, Antonello, Guglielmini, Pamela Francesca, Maruzzo, Marco, Rossi, Ernesto, Grossi, Francesco, Casadei, Chiara, Cortellini, Alessio, Verderame, Francesco, Montesarchio, Vincenzo, Rizzo, Mimma, Mencoboni, Manlio, Fable Zustovich, Fratino, Lucia, Cinieri, Saverio, Negrini, Giorgia, Banzi, Maria, Sorarù, Mariella, Zucali, Paolo Andrea, Lacidogna, Gaetano, Russo, Antonio, Battelli, Nicola, Fornarini, Giuseppe, Mucciarini, Claudia, Bracarda, Sergio, Bonetti, Andrea, Pezzuolo, Debora, Longo, Lucia, Sartori, Donata, Iannopollo, Mauro, Cavanna, Luigi, Meriggi, Fausto, Tassinari, Davide, Corbo, Claudia, Gernone, Angela, Prati, Veronica, Carnio, Simona, Giordano, Pasqualina, Dicorato, Angela Maria, Verusio, Claudio, Atzori, Francesco, Carrozza, Francesco, Gori, Stefania, Castro, Antonino, Pilotto, Sara, Vaccaro, Vanja, Garzoli, Elisabetta, Costanzo, Francesco Di, Maiello, Evaristo, Labianca, Roberto, Pinto, Carmine, Tognetto, Michele, and Buti, Sebastiano

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplementary_Material_-_online_only for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG by Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Elena Verzoni, Alberto Clemente, Valentina Guadalupi, Diego Signorelli, Marcello Tiseo, Raffaele Giusti, Marco Filetti, Marilena Di Napoli, Lorenzo Calvetti, Alessandro Cappetta, Paola Ermacora, Diego Zara, Fausto Barbieri, Cinzia Baldessari, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casadei, Alessio Cortellini, Francesco Verderame, Vincenzo Montesarchio, Mimma Rizzo, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Saverio Cinieri, Giorgia Negrini, Maria Banzi, Mariella Sorarù, Paolo Andrea Zucali, Gaetano Lacidogna, Antonio Russo, Nicola Battelli, Giuseppe Fornarini, Claudia Mucciarini, Sergio Bracarda, Andrea Bonetti, Debora Pezzuolo, Lucia Longo, Donata Sartori, Mauro Iannopollo, Luigi Cavanna, Fausto Meriggi, Davide Tassinari, Claudia Corbo, Angela Gernone, Veronica Prati, Simona Carnio, Pasqualina Giordano, Angela Maria Dicorato, Claudio Verusio, Francesco Atzori, Francesco Carrozza, Stefania Gori, Antonino Castro, Sara Pilotto, Vanja Vaccaro, Elisabetta Garzoli, Francesco Di Costanzo, Evaristo Maiello, Roberto Labianca, Carmine Pinto, Michele Tognetto and Sebastiano Buti in Therapeutic Advances in Medical Oncology

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results